开云app官网登录入口网页版-官方正版

#KRAS抑制剂#

9篇内容 | 1224人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2217398, encodeId=5deb221e39827, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a> <a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a> <a href='/topic/show?id=c4b411e24281' target=_blank style='color:#2F92EE;'>#RMC-6236#</a>, objectTitle=RMC-6236通杀KRAS所有突变，有望成为新一代王者, objectType=article, longId=836800, objectId=4aa5836800df, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240729/95cb13f4de0e4067b8040754e71abe17-PCh0QKIF1r87.jpg, objectUrl=/article/show_article.do?id=4aa5836800df, replyNumber=0, likeNumber=65, createdTime=2024-07-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=4aa5836800df, moduleTitle=RMC-6236通杀KRAS所有突变，有望成为新一代王者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4aa5836800df)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2181538, encodeId=0c3d218153872, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=KRAS突变抑制剂最新汇总与对比：肺癌，胰腺癌，结直肠癌......, objectType=article, longId=809328, objectId=7427809328dc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240113/8450c162a88d45379bdf9761f1c07713.jpg, objectUrl=/article/show_article.do?id=7427809328dc, replyNumber=0, likeNumber=83, createdTime=2024-01-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=7427809328dc, moduleTitle=KRAS突变抑制剂最新汇总与对比：肺癌，胰腺癌，结直肠癌......, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7427809328dc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2155767, encodeId=d2682155e67d7, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>与<a href='/topic/show?id=e6dd29094a1' target=_blank style='color:#2F92EE;'>#免疫疗法#</a>组合治疗<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>临床试验开始, objectTitle=Cancer Cell：KRAS抑制剂与免疫疗法组合治疗胰腺癌临床试验开始, objectType=article, longId=789676, objectId=6454e8967636, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=6454e8967636, replyNumber=0, likeNumber=98, createdTime=2023-09-02, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6454e8967636, moduleTitle=Cancer Cell：KRAS抑制剂与免疫疗法组合治疗胰腺癌临床试验开始, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6454e8967636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602797, encodeId=3afd1602e9740, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果, objectType=article, longId=218574, objectId=67f02185e4be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67f02185e4be, replyNumber=0, likeNumber=84, createdTime=2021-10-16, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67f02185e4be, moduleTitle=KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=67f02185e4be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602796, encodeId=30131602e96c2, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=NEJM：KRAS抑制剂获得性耐药机制研究, objectType=article, longId=213196, objectId=8eda2131962c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eda2131962c, replyNumber=0, likeNumber=78, createdTime=2021-06-26, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eda2131962c, moduleTitle=NEJM：KRAS抑制剂获得性耐药机制研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8eda2131962c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602795, encodeId=17cb1602e95a0, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌, objectType=article, longId=212097, objectId=f6de21209e2c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6de21209e2c, replyNumber=0, likeNumber=89, createdTime=2021-06-02, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6de21209e2c, moduleTitle=KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f6de21209e2c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602794, encodeId=1d3c1602e9432, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, objectType=article, longId=205368, objectId=7c3220536802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c3220536802, replyNumber=0, likeNumber=99, createdTime=2021-01-07, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c3220536802, moduleTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7c3220536802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602793, encodeId=51341602e935e, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请, objectType=article, longId=204984, objectId=f80e2049842c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f80e2049842c, replyNumber=0, likeNumber=72, createdTime=2020-12-31, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f80e2049842c, moduleTitle=安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f80e2049842c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602792, encodeId=c1fd1602e9247, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, objectType=article, longId=202536, objectId=c48320253636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48320253636, replyNumber=0, likeNumber=69, createdTime=2020-10-28, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48320253636, moduleTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c48320253636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602791, encodeId=7c4f1602e9140, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=Nature：临床KRAS抑制剂AMG 510驱动抗肿瘤免疫, objectType=article, longId=182273, objectId=c5e61822e3a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e61822e3a2, replyNumber=0, likeNumber=76, createdTime=2019-11-04, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e61822e3a2, moduleTitle=Nature：临床KRAS抑制剂AMG 510驱动抗肿瘤免疫, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c5e61822e3a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1602790, encodeId=20411602e90b8, content=<a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=WCLC 2019：KRAS抑制剂AMG 510显著缩小了NSCLC患者的肿瘤, objectType=article, longId=179175, objectId=f41b1e9175df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f41b1e9175df, replyNumber=0, likeNumber=86, createdTime=2019-09-10, rootId=0, userName=360611846, userId=41d718933852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f41b1e9175df, moduleTitle=WCLC 2019：KRAS抑制剂AMG 510显著缩小了NSCLC患者的肿瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f41b1e9175df)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

KRAS抑制剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS突变# #KRAS抑制剂# #RMC-6236#

RMC-6236通杀KRAS所有突变，有望成为新一代王者

2024-07-29发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#胰腺癌# #KRAS# #KRAS抑制剂#

KRAS突变抑制剂最新汇总与对比：肺癌，胰腺癌，结直肠癌......

2024-01-14发表于加利福尼亚

侠胆医心 (审核中...)

前往app查看评论内容

#KRAS抑制剂#与#免疫疗法#组合治疗#胰腺癌#临床试验开始

Cancer Cell：KRAS抑制剂与免疫疗法组合治疗胰腺癌临床试验开始

2023-09-02发表于上海

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

KRAS G12C突变癌症治疗新突破，KRAS抑制剂的新组合显示积极结果

2021-10-16

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

NEJM：KRAS抑制剂获得性耐药机制研究

2021-06-26

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌

2021-06-02

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比

2021-01-07

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请

2020-12-31

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展

2020-10-28

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

Nature：临床KRAS抑制剂AMG 510驱动抗肿瘤免疫

2019-11-04

360611846 (审核中...)

前往app查看评论内容

#KRAS抑制剂#

WCLC 2019：KRAS抑制剂AMG 510显著缩小了NSCLC患者的肿瘤

2019-09-10

科室
- - 订阅+
  - 更多科室
工具
服务